TSTickerStarGet alerts

HCW Biologics Reports Q3 2026 Financial Results

HCW Biologics reported Q3 2026 revenues of $55,463, up from $15,606 in Q3 2025, and net loss of $3.2 million compared to $4.6 million in the prior year period. For the nine months ended September 30, 2026, revenues were $6.7 million versus $27,222 in the prior year period, primarily driven by the Trimmune licensing agreement, while net loss improved to $5.0 million from $8.7 million. The company disclosed substantial doubt about its ability to continue as a going concern for at least 12 months without additional...

Share this story

Key takeaways

  • Revenues: Q3 2026 revenue increased 255% year-over-year to $55,463; nine-month revenue surged to $6.7 million from $27,222, driven by the Beijing Trimmune licensing agreement.

  • Net loss: Q3 2026 net loss improved 29% to $3.2 million versus $4.6 million in Q3 2025; nine-month net loss narrowed to $5.0 million from $8.7 million.

  • Operating expenses: R&D expenses decreased 12% to $1.2 million in Q3 2026; G&A expenses declined 28% to $1.4 million.

  • Going concern: The company stated substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the financial statement issuance date without additional funding.

  • Financing: The company raised $8.6 million in equity financing in the nine months ended September 30, 2026 and secured up to $10 million in debt financing on November 4, 2026.

  • Clinical progress: HCW9302 Phase 1 readout in alopecia areata is expected in Q1 2027; FDA provided guidance for IND application for HCW11-018b with filing planned for H1 2027.

Key metrics

Revenues - Q3Q3 2026 (quarter ended September 30, 2026)
$55,463+255%
Revenues - Nine monthsNine months ended September 30, 2026
$6.7 million+24,609%
Net loss - Q3Q3 2026
$3.2 million-29%
Net loss - Nine monthsNine months ended September 30, 2026
$5.0 million-43%
Operating loss - Q3Q3 2026
$2.6 million-21%
Operating expenses - Q3 R&DQ3 2026
$1.2 million-12%
Operating expenses - Q3 G&AQ3 2026
$1.4 million-28%
Net loss per share - Q3Q3 2026
$2.83-76%

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow HCWB in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert